JPH0243726B2 - - Google Patents
Info
- Publication number
- JPH0243726B2 JPH0243726B2 JP56044343A JP4434381A JPH0243726B2 JP H0243726 B2 JPH0243726 B2 JP H0243726B2 JP 56044343 A JP56044343 A JP 56044343A JP 4434381 A JP4434381 A JP 4434381A JP H0243726 B2 JPH0243726 B2 JP H0243726B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- lactam
- antibacterial activity
- present
- antibacterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims description 21
- 230000000844 anti-bacterial effect Effects 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 20
- 239000002132 β-lactam antibiotic Substances 0.000 claims description 19
- 229940124586 β-lactam antibiotics Drugs 0.000 claims description 19
- 229940124349 antibacterial activity enhancer Drugs 0.000 claims description 8
- 229960000723 ampicillin Drugs 0.000 claims description 7
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 7
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 claims description 7
- 229960003866 cefaloridine Drugs 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 4
- 229960003022 amoxicillin Drugs 0.000 claims description 3
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 description 10
- 239000003242 anti bacterial agent Substances 0.000 description 10
- 230000003115 biocidal effect Effects 0.000 description 10
- 108090000204 Dipeptidase 1 Proteins 0.000 description 9
- 102000006635 beta-lactamase Human genes 0.000 description 9
- 229940125904 compound 1 Drugs 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 229940088710 antibiotic agent Drugs 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000003623 enhancer Substances 0.000 description 6
- -1 3-phthalidyl group Chemical group 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 108010087702 Penicillinase Proteins 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 244000000010 microbial pathogen Species 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229950009506 penicillinase Drugs 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 150000002960 penicillins Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- JETQIUPBHQNHNZ-NJBDSQKTSA-N (2s,5r,6r)-3,3-dimethyl-7-oxo-6-[[(2r)-2-phenyl-2-sulfoacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound C1([C@H](C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)S(O)(=O)=O)=CC=CC=C1 JETQIUPBHQNHNZ-NJBDSQKTSA-N 0.000 description 1
- 125000005846 1-(alkanoyloxy)ethyl group Chemical group 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- UQLLWWBDSUHNEB-CZUORRHYSA-N Cefaprin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CSC1=CC=NC=C1 UQLLWWBDSUHNEB-CZUORRHYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 125000005850 N-(alkoxycarbonyl)aminomethyl group Chemical group 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 1
- 125000005206 alkoxycarbonyloxymethyl group Chemical group 0.000 description 1
- XMQVYNAURODYCQ-SLFBBCNNSA-N apalcillin Chemical compound C1([C@@H](NC(=O)C=2C(=C3N=CC=CC3=NC=2)O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 XMQVYNAURODYCQ-SLFBBCNNSA-N 0.000 description 1
- 229950001979 apalcillin Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- RRYMAQUWDLIUPV-BXKDBHETSA-N cefacetrile Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC#N)[C@@H]12 RRYMAQUWDLIUPV-BXKDBHETSA-N 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- 229960004350 cefapirin Drugs 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- HGBLNBBNRORJKI-WCABBAIRSA-N cyclacillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C1(N)CCCCC1 HGBLNBBNRORJKI-WCABBAIRSA-N 0.000 description 1
- 229960004244 cyclacillin Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- DXVUYOAEDJXBPY-NFFDBFGFSA-N hetacillin Chemical compound C1([C@@H]2C(=O)N(C(N2)(C)C)[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 DXVUYOAEDJXBPY-NFFDBFGFSA-N 0.000 description 1
- 229960003884 hetacillin Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000003951 lactams Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 1
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960004932 sulbenicillin Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4434381A JPS57158722A (en) | 1981-03-25 | 1981-03-25 | Antimicrobial activity enhancer and antimicrobial composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4434381A JPS57158722A (en) | 1981-03-25 | 1981-03-25 | Antimicrobial activity enhancer and antimicrobial composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS57158722A JPS57158722A (en) | 1982-09-30 |
JPH0243726B2 true JPH0243726B2 (is) | 1990-10-01 |
Family
ID=12688861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP4434381A Granted JPS57158722A (en) | 1981-03-25 | 1981-03-25 | Antimicrobial activity enhancer and antimicrobial composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS57158722A (is) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0481830U (is) * | 1990-11-28 | 1992-07-16 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6143116A (ja) * | 1984-08-03 | 1986-03-01 | Shionogi & Co Ltd | 細菌性感染症の治療および治療薬 |
WO2024160247A1 (zh) * | 2023-02-02 | 2024-08-08 | 苏州信诺维医药科技股份有限公司 | 含β-内酰胺酶抑制剂的药物组合物及其应用 |
-
1981
- 1981-03-25 JP JP4434381A patent/JPS57158722A/ja active Granted
Non-Patent Citations (1)
Title |
---|
J.MED.CHEM * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0481830U (is) * | 1990-11-28 | 1992-07-16 |
Also Published As
Publication number | Publication date |
---|---|
JPS57158722A (en) | 1982-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5809750B2 (ja) | β−ラクタム抗生物質、スルバクタム及びβ−ラクタマーゼ阻害薬を含む医薬組成物 | |
US20200093814A1 (en) | Combination therapy with amidine substituted beta-lactam compounds and beta-lactamase inhibitors for infections with antibiotic resistant bacterial strains | |
KR950703346A (ko) | 결정성 페니실린 유도체, 그의 제법 및 용도(Crystalline Penicillin Derivative, and Its Production and Use) | |
JP5961177B2 (ja) | 化合物及びその使用 | |
EP0680322B1 (en) | Use of clavulanate and an antibacterial compound for the treatment of infections | |
Cole | ‘β-Lactams’ as β-lactamase inhibitors | |
EP2167081B1 (en) | Bactericidal anti-mrsa active pharmaceutical composition containing carbapenems | |
US4263280A (en) | Synergistic mixtures | |
JPH0243726B2 (is) | ||
US20030109503A1 (en) | Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics | |
Bryskier | Penicillins | |
US4324783A (en) | Antibacterial composition for medical use | |
Webber et al. | Antimicrobial and pharmacokinetic properties of newer penicillins and cephalosporins | |
US5049384A (en) | Antibacterial composition for medical use and a process for the preparation thereof | |
EP0003618B1 (en) | Antibacterial composition and use thereof | |
WO1994027600A1 (en) | Pharmaceutical formulations with clavulanic acid and an antimycobacterial agent | |
EP3402777B1 (en) | Oxazolidinones as taro inhibitors | |
US4428936A (en) | Antibacterial composition for medical use | |
US4330529A (en) | Antibacterial composition | |
US3952094A (en) | Antibacterial compositions | |
Turck | Introduction: Cephalosporins and Related Antibiotics: An Overview | |
US3953593A (en) | Antibacterial compositions | |
GB2157284A (en) | 6- beta -halopenicillanic acid salts | |
HU181974B (hu) | Eljárás cefem-karbonsav-származékol és p-laktamáz inhibitort tartalmazó baktériumellenes hatású gyógyszerkészítmények előállítására | |
JPS61218520A (ja) | 感染症治療剤 |